Search results for "Nonalcoholic steatohepatitis"

showing 10 items of 30 documents

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

2021

[Background and Aims] Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) have been proposed as non-invasive tests for patients with non-alcoholic fatty liver disease (NAFLD). This study evaluated their diagnostic accuracy for liver fibrosis and non-alcoholic steatohepatitis (NASH).

0301 basic medicineFIBROSIS NONINVASIVE ASSESSMENTCirrhosisTransient elastographydeMILI0302 clinical medicineMedicineBARIATRIC SURGERY CANDIDATESNon-alcoholic steatohepatitismedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISFatty liverMagnetic Resonance Imaging3. Good healthArea Under CurveLiver biopsyElasticity Imaging TechniquesNASH-MRI030211 gastroenterology & hepatologyBio-markersRadiologyElastographyDiffusion-weighted imagingLife Sciences & BiomedicineAdultPREDICTS ADVANCED FIBROSISmedicine.medical_specialtyBiomarkers deMILI Diffusion-weighted imaging Magnetic resonance elastography NASH-MRI Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Shear wave elastography Transient elastography AdultArea Under Curve Elasticity Imaging Techniques Humans Magnetic Resonance Imaging Non-alcoholic Fatty Liver Disease ROC Curve fibro-MRI Iron-corrected T1 Liver fibrosisLiver fibrosisCONTROLLED ATTENUATION PARAMETERSTIFFNESS MEASUREMENT03 medical and health sciencesIron-corrected T1HumansFATTY LIVER-DISEASEScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryRADIATION FORCE IMPULSEMagnetic resonance imagingmedicine.diseaseCONTROLLED TRANSIENT ELASTOGRAPHYMagnetic resonance elastography030104 developmental biologyROC CurveMagnetic resonance elastographyShear wave elastographyXL PROBEHuman medicinefibro-MRISteatohepatitisbusinessTransient elastographyBiomarkersNon-alcoholic fatty liver diseaseJournal of Hepatology
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods

2020

Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population; however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring systems for defining fibrosis. Methods. US and intraoperative liver b…

AdultMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaArticle SubjectPopulationBariatric SurgeryPrevalence NAFLD Fibrosis Bariatric Surgery Non invasive diagnosis UltrasoundGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseDiabetes mellitusNonalcoholic fatty liver diseasemedicinePrevalenceHumansObesityeducationNonalcoholic steatohepatitis (NASH)Retrospective StudiesUltrasonographyeducation.field_of_studyGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industryFatty liverRRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseFibrosisSurgeryObesity Morbidultrasound (US)ROC Curve030220 oncology & carcinogenesisLiver biopsyMedicine030211 gastroenterology & hepatologyFemalebusinessResearch ArticleNonalcoholic fatty liver disease (NAFLD)BioMed Research International
researchProduct

The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis

2015

Background & Aims Uncoupling protein 2 - UCP2 - regulates mitochondrial lipid fluxes and reactive oxygen species production by the respiratory chain. The −866 G>A UCP2 promoter region polymorphism has been linked to insulin resistance and lipid metabolism. The aim of this study was to assess whether the −866 G>A UCP2 polymorphism predisposes to nonalcoholic steatohepatitis in patients at risk, and the relationship with lipid metabolism and hepatic UCP2 expression. Methods We considered 688 Italian patients who underwent liver biopsy for suspected NASH, and 232 healthy controls. The UCP2 −866 G>A polymorphism was determined by allele specific oligonucleotide probes, hepatic UCP2 mRNA levels …

AdultMalemedicine.medical_specialtyGenotypeRespiratory chainGene ExpressionBiologyIon ChannelsMitochondrial Proteinsgenetic polymorphism; lipid metabolism;liver; mitochondria; nonalcoholic steatohepatitis; uncoupling protein-2Insulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsDiabetes mellitusInternal medicineGenotypemedicineHumansUncoupling Protein 2Promoter Regions GeneticUncoupling protein-2AllelesAgedPolymorphism GeneticGenetic polymorphismmedicine.diagnostic_testHepatologyLipid metabolismMiddle Agedmedicine.diseaseImpaired fasting glucoseMitochondriaEndocrinologyLogistic ModelsLipid metabolismLiverLiver biopsyCase-Control StudiesFemaleSteatosisInsulin ResistanceNonalcoholic steatohepatiti
researchProduct

High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steato…

2011

Abstract Background and aim To investigate the hepatic expression of retinol-binding protein-4 (RBP4) in chronic hepatitis C (CHC) and nonalcoholic steatohepatitis (NASH) patients, and its association with biochemical and histological patterns of liver damage. Materials and methods Sixty-six genotype 1 CHC and 32 NASH patients were tested for hepatic RBP4 expression. Liver expression at immunostaining was scored as 0 (slight), 1 (mild), 2 (moderate), and 3 (intense). In addition, the mRNA and the quantitative protein expressions of RBP4 were tested by PCR and by western blot, respectively, in 12 NASH and 28 CHC patients. Twelve subjects undergoing elective cholecystectomy served as controls…

AdultMalemedicine.medical_specialtyLogistic ModelFibrosiHepatitis C virusInflammationSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyBody Mass IndexWestern blotFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineGenotypeMedicineHumansAge FactorRNA MessengerHEPATIC STEATOSISRetinol binding protein 4Settore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbiologyNONALCOHOLIC STEATOHEPATITISbusiness.industryGastroenterologyAge FactorsHEPATITIS C VIRUSHepatitis C ChronicMiddle Agedmedicine.diseaseFibrosisFatty LiverLogistic Modelsbiology.proteinmedicine.symptomSteatosisInsulin ResistanceWaist CircumferenceRetinol binding protein-4businessRetinol-Binding Proteins PlasmaImmunostainingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.

2013

Background and Aim To evaluate if the presence of carotid atherosclerosis in patients with NAFLD, could be related to gene variants influencing hepatic fat accumulation and the severity of liver damage. Methods We recorded anthropometric, metabolic and histological data(Kleiner score) of 162 consecutive, biopsy-proven Sicilian NAFLD patients. Intima-media thickness(IMT), IMT thickening(IMT≥1 mm) and carotid plaques(focal thickening of >1.3 mm at the level of common carotid artery) were evaluated using ultrasonography. IL28B rs12979860 C>T, PNPLA3 rs738409 C>G, GCKR rs780094 C>T, LYPLAL1 rs12137855 C>T, and NCAN rs2228603 C>T single nucleotide polymorphisms were also assessed. The results we…

Carotid Artery DiseasesMalePathologylcsh:MedicineGastroenterology0302 clinical medicinePolymorphism (computer science)Non-alcoholic Fatty Liver DiseaseRisk FactorsGenotypeCommon carotid arterylcsh:ScienceATEROSCLEROSI0303 health sciencesMultidisciplinaryNONALCOHOLIC STEATOHEPATITISFatty liverMiddle Aged3. Good healthCarotid ArteriesCohortcardiovascular system030211 gastroenterology & hepatologyFemaleResearch ArticleAdultmedicine.medical_specialtyGenotypeSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesmedicine.arteryDiabetes mellitusInternal medicinemedicineHumansClinical significancecardiovascular diseasesAllelesGenetic Association StudiesPNPLA3030304 developmental biologyAgedNAFLD PNPLA3 ATHEROSCLEROSISbusiness.industrylcsh:RMembrane ProteinsLipasemedicine.diseaseFatty Liverlcsh:Qbusiness
researchProduct

Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet.

2015

Contains fulltext : 155347.pdf (Publisher’s version ) (Closed access) BACKGROUND/OBJECTIVES: In the context of obesity, epigenetic mechanisms regulate cell-specific chromatin plasticity, perpetuating gene expression responses to nutrient excess. MacroH2A1, a variant of histone H2A, emerged as a key chromatin regulator sensing small nutrients during cell proliferation and differentiation. Mice genetically ablated for macroH2A1 (knockout (KO)) do not show overt phenotypes under a standard diet. Our objective was to analyse the in vivo role of macroH2A1 in response to nutritional excess. METHODS: Twelve-week-old whole-body macroH2A1 KO male mice were given a high-fat diet (60% energy from lard…

EXPRESSIONCHROMATINNonalcoholic steatohepatitisModels Molecularmedicine.medical_specialtyHISTONE VARIANT MACROH2Amacrohistone H2A1 High fat diet obesity.Endocrinology Diabetes and MetabolismLIVER-DISEASE NAFLDTHERMOGENESISMedicine (miscellaneous)Adipose tissueBiologyDiet High-FatCell LineHistonesMiceINFLAMMATIONAdipose Tissue BrownThinnessInternal medicineBINDINGmedicineAnimalsGenetic ablationNutrition and DieteticsAdipogenesisNONALCOHOLIC STEATOHEPATITISTRANSCRIPTIONAL COREGULATOR PELP1medicine.diseaseNUTRITION&DIETETICSObesityDisease Models AnimalRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]EndocrinologyEnergy expenditureFat dietOBESITYInsulin ResistanceEnergy MetabolismThermogenesisInternational journal of obesity (2005)
researchProduct

Genetic background in nonalcoholic fatty liver disease: A comprehensive review

2015

In the Western world, nonalcoholic fatty liver disease (NAFLD) is considered as one of the most significant liver diseases of the twenty-first century. Its development is certainly driven by environmental factors, but it is also regulated by genetic background. The role of heritability has been widely demonstrated by several epidemiological, familial, and twin studies and case series, and likely reflects the wide inter-individual and inter-ethnic genetic variability in systemic metabolism and wound healing response processes. Consistent with this idea, genome-wide association studies have clearly identified Patatin-like phosholipase domain-containing 3 gene variant I148M as a major player i…

Genetic MarkersCandidate geneGenome-wide association studieHeredityPatatin-like phospholipase domain-containing 3Genome-wide association studyDiseaseReviewBiologymedicine.disease_causeGeneticNon-alcoholic Fatty Liver DiseaseRisk FactorsHeredityNonalcoholic fatty liver diseasemedicineHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic variabilityGenetic associationGeneticsFatty liverGastroenterologyGenetic VariationGeneral Medicinemedicine.diseaseCandidate gene studiePedigreePhenotypeNonalcoholic steatohepatitiTransmembrane 6 superfamily member 2Candidate gene studies; Genetics; Genome-wide association studies; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Patatin-like phospholipase domain-containing 3; Transmembrane 6 superfamily member 2Genome-Wide Association Study
researchProduct

PSD3 downregulation confers protection against fatty liver disease

2022

Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a missing heritability component. Using a candidate gene approach, we identify a locus (rs71519934) at the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene resulting in a leucine to threonine substitution at position 186 of the protein (L186T) that reduces susceptibility to the entire spectrum of FLD in individuals at risk. PSD3 downregulation by short interfering RNA reduces intracellular lipid content in primary human hepatocytes cultured in two and three dimensions, and in human and rodent hepatoma cell…

GenotypeEndocrinology Diabetes and MetabolismVARIANTSUSCEPTIBILITYPolymorphism Single NucleotideArticleCell LineMiceRibonucleasesPhysiology (medical)Internal MedicineAnimalsGuanine Nucleotide Exchange FactorsHumansRNA-SeqAllelesNon-alcoholic steatohepatitisNONALCOHOLIC STEATOHEPATITISHERITABILITYGene Expression ProfilingfungiNASHGenetic VariationCell BiologyMetabolic syndromeFatty LiverMetabolismGene Expression RegulationLiverEXOME-WIDE ASSOCIATION3121 General medicine internal medicine and other clinical medicineACIDHepatocytesSECRETIONDisease SusceptibilityVLDLBiomarkersTRIGLYCERIDESNon-alcoholic fatty liver disease
researchProduct

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

2020

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence …

Liver Cirrhosis0301 basic medicineCirrhosisDiagnostic criteriaCirrhosis; Diabetes; Diagnostic criteria; MAFLD; Metabolic; NAFLD; Obesity; Steatohepatitis[SDV]Life Sciences [q-bio]HISTOLOGIC FEATURESPROGRESSIONDiseaseTerminology0302 clinical medicineMedicine10. No inequalitySteatohepatitisNONALCOHOLIC STEATOHEPATITISFatty liverHIGH BLOOD-PRESSUREDiabetesHEALTHY OBESE3. Good healthPREVALENCECausalityCirrhosisDisease Progression030211 gastroenterology & hepatologymedicine.medical_specialtyConsensusMAFLDDIAGNOSIS03 medical and health sciencesMetabolic DiseasesTerminology as TopicDiabetes mellitusNAFLDMANAGEMENTHumansObesityIntensive care medicineHepatologybusiness.industryType 2 Diabetes MellitusNATURAL-HISTORYmedicine.diseaseFatty LiverClinical trial030104 developmental biologyDiabetes Mellitus Type 2MetabolicSteatohepatitisbusiness
researchProduct